To study the dynamics of serum levels of vascular remodeling in patients with hypertension, including in combination with type 2 diabetes mellitus during 12‑month therapy with perindopril A

Aim      To study the dynamics of serum markers for vascular remodeling in patients with arterial hypertension (AH), including AH associated with type 2 diabetes mellitus (DM2) during the 12-month treatment with the angiotensin-converting enzyme (ACE) inhibitor, perindopril A.

Material and methods  The study included patients with grade 1-2 AH with or without type 2 DM (30 and 32, respectively). Perindopril A 10 mg/day was administered for the outpatient correction of previous, ineffective antihypertensive therapy. The following biomarkers were measured for all patients at baseline and at 12 months: matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), E-selectin, endothelin 1, transforming growth factor β-1 (TGF-β1), and von Willebrand factor (WF). Laboratory tests were performed with enzyme immunoassay.

Results After 12 months of the perindopril A (perindopril arginine) 10 mg/day treatment, both groups achieved the goal blood pressure. Evaluation of biomarker dynamics during the perindopril A treatment showed significant decreases in MMP-9, TIMP-1, and endothelin 1 in the AH group; then the level of TIMP-1 returned to normal values (р<0.05). In the AH+DM2 group, the MMP-9 concentration was significantly decreased (р<0.05); the other values did not show any significant differences. In both groups, MMP-9 was significantly decreased (28.6 % (р=0.01) in group 1 and 33.2 % (р=0.00) in group 2. Notably, in none of these groups, did this index reach normal values. Also, there were no significant differences in this index between the groups (р=0.66). It should be noted that the decreases in TIMP-1 were significantly different between the groups (р=0.001). Thus, this biomarker did not significantly decrease in patients with AH and DM2 (р=0.26) whereas in group 1 (AH without DM2), the level of TIMP-1 decreased by 39.3 % and reached the normal range (р=0.005).

Conclusion      Concentrations of biomarkers were decreased in both groups. However, in the AH group, there were statistically significant decreases in the markers that reflect processes of fibrosis and vasoconstriction. At the same time in the AH+DM2 group, there was no significant dynamics of the biomarkers, which was most likely due to more pronounced damage of blood vessels. However, the decrease in MMP-9 may indicate an alleviation of fibrotic processes in arterial walls. These results allow a conclusion that the long-term treatment with the ACE inhibitor, perindopril A, may reverse remodeling of the vascular changes that are called “early vascular ageing”.

r aging".

1. Yasmin, Wallace S, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K et al. Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(2):372–8. DOI: 10.1161/01.ATV.0000151373.33830.41

2. Vatutin N.T., Sklyannaya E.V. Prevalence of arterial hypertension and risk factors in young adults. Archive of internal medicine. 2017;7(1):30–4. DOI: 10.20514/2226-6704-2017-7-1-30-34

3. Dedov I.I., Shestakova M.V., Mayorov A.Yu., Vikulova O.K., Galstyan G.R., Kuraeva T.L. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 8th edition. Diabetes mellitus. 2017;20(1S):1–121. DOI: 10.14341/DM20171S8

4. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149– 218. DOI: 10.15829/1560-4071-2020-3-3786

5. Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. Canadian Journal of Cardiology. 2016;32(5):659–68. DOI: 10.1016/j.cjca.2016.02.070

6. Castorena-Gonzalez JA, Staiculescu MC, Foote C, Martinez-Lemus LA. Mechanisms of the Inward Remodeling Process in Resistance Vessels: Is the Actin Cytoskeleton Involved? Microcirculation. 2014;21(3):219–29. DOI: 10.1111/micc.12105

7. Sato Y, Yamamoto E, Sawa T, Toda K, Hara T, Iwasaki T et al. Highsensitivity cardiac troponin T in essential hypertension. Journal of Cardiology. 2011;58(3):226–31. DOI: 10.1016/j.jjcc.2011.07.009

8. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31(7):1281–357. DOI: 10.1097/01.hjh.0000431740.32696.cc

9. Oliver JJ, Webb DJ, Newby DE. Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(12):2470–9. DOI: 10.1161/01.ATV.0000189309.05924.88

10. Burdick MM, Bochner BS, Collins BE, Schnaar RL, Konstantopoulos K. Glycolipids Support E-Selectin-Specific Strong Cell Tethering under Flow. Biochemical and Biophysical Research Communications. 2001;284(1):42–9. DOI: 10.1006/bbrc.2001.4899

11. Hamsten A. The hemostatic system and coronary heart disease. Thrombosis Research. 1993;70(1):1–38. DOI: 10.1016/0049-3848(93)90221-9

12. Over J, Sixma JJ, Bruïne MH, Trieschnigg MC, Vlooswijk RA, Beeser-Visser NH et al. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. Journal of Clinical Investigation. 1978;62(2):223–34. DOI: 10.1172/JCI109120

13. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clinical Cardiology. 2003;26(2):55–9. DOI: 10.1002/clc.4960260203

14. Manna P, Jain SK. Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metabolic Syndrome and Related Disorders. 2015;13(10):423– 44. DOI: 10.1089/met.2015.0095

15. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease. Circulation. 2003;107(12):1579–85. DOI: 10.1161/01.CIR.0000058700.41738.12

16. Rogova L.N., Shesternina N.V., Zamechnik T.V., Fastova I.A. Matrix metalloproteinases, their role in physiological and pathological processes (review). Bulletin of New Medical Technologies. 2011;18(2):86–9.

17. Opgaard OS, Cantera L, Adner M, Edvinsson L. Endothelin-A and -B receptors in human coronary arteries and veins. Regulatory Peptides. 1996;63(2–3):149–56. DOI: 10.1016/0167-0115(96)00036-5

18. Vasina L.V., Petrishchev N.N., Vlasov T.D. Markers of endothelial dysfunction. Regional blood circulation and microcirculation. 2017;16(1):4–15. DOI: 10.24884/1682-6655-2017-16-1-4-15

19. Mourad J-J, Waeber B, Zannad F, Laville M, Duru G, Andréjak M. Comparison of different therapeutic strategies in hypertension: a lowdose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. Journal of Hypertension. 2004;22(12):2379–86. DOI: 10.1097/00004872-200412000-00021

20. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S et al. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial. Stroke. 2004;35(1):116–21. DOI: 10.1161/01.STR.0000106480.76217.6F

21. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–324. DOI: 10.1161/HYP.0000000000000066

22. Toto RD, Rinner S, Ram CVS. ACE inhibitors and target organ protection: An expanded role for these antihypertensive agents? Postgraduate Medicine. 2004;116(2):11–48. DOI: 10.3810/pgm.2004.08.1567

23. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C et al. Role of Matrix Metalloproteinases in Early Hypertensive Vascular Remodeling. Hypertension. 2007;50(1):212–8. DOI: 10.1161/HYPERTENSIONAHA.107.089631

24. Scientific Committee of the PERTINENT Sub-Study, EUROPAPERTINENT Investigators. PERTINENT – perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovascular Drugs and Therapy. 2003;17(1):83–91. DOI: 10.1023/a:1024394610648

25. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837–53. DOI: 10.1016/S0140-6736(98)07019-6

26. Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ et al. The Cardioprotective Effects of the AngiotensinConverting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency: insights from the EUROPA trial. Journal of the American College of Cardiology. 2007;50(22):2148–55. DOI: 10.1016/j.jacc.2007.08.029

27. Moskalenko M.I. The involvement of genes of matrix metalloproteinases in the development of arterial hypertension and its complication (review). Research Result. Medicine and Pharmacy. 2018;4(1):53– 69. DOI: 10.18413/2313-8955-2018-4-1-53-69

28. Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Zyubanova I.V., Sitkova E.S. et al. Matrix metalloproteinases in patients with resistant hypertension and type 2 diabetes mellitus: relation with renal blood flow and kidney function. Arterial Hypertension. 2019;25(1):34–45. DOI: 10.18705/1607-419X-2019-25-1-34-45

29. Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I et al. Targeting vascular (endothelial) dysfunction: Targeting vascular (endothelial) dysfunction. British Journal of Pharmacology. 2017;174(12):1591–619. DOI: 10.1111/bph.13517

30. Giles LV, Tebbutt SJ, Carlsten C, Koehle MS. The effect of low and high-intensity cycling in diesel exhaust on flow-mediated dilation, circulating NOx, endothelin-1 and blood pressure. PLOS ONE. 2018;13(2):e0192419. DOI: 10.1371/journal.pone.0192419

31. Stepanova Yu.I., Gonchar I.A. Endothelin-dependent effects in cerebrovascular pathology of ischemic genesis. Medical news. 2013;10:12–8.

32. Hlubocká Z, Umnerová V, Heller S, Peleska J, Jindra A, Jáchymová M et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. Journal of Human Hypertension. 2002;16(8):557–62. DOI: 10.1038/sj.jhh.1001403

33. Valente FM, de Andrade DO, Cosenso-Martin LN, Cesarino CB, Guimarães SM, Guimarães VB et al. Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis. BMC Cardiovascular Disorders. 2020;20(1):132. DOI: 10.1186/s12872-020-01412-5